Diabetes Obesity and Metabolism · 2020 · 13 citations · 32 references
MedicineEndocrinologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyDiabetologyDiabetes ControlDiabetes MellitusDiabetes PharmacotherapyGlucagon-like Peptide-1 Receptor AgonistsGlycemic ControlInsulin TherapyAdd-on TherapyCardiovascular Disease BiomarkersFat-free MassGlucagon-like Peptide 1 Receptor AgonismGlucagon-like PeptidesShort-acting Glp-1 Receptor AgonistsSmall-molecule Glp-1 Receptor AgonistsType 1 Diabetes Pharmacotherapy
AIMS: To investigate the effect of adding the short-acting glucagon-like peptide 1 receptor agonist (GLP-1RA) exenatide to insulin treatment on markers of cardiovascular risk in type 1 diabetes. MATERIALS AND METHODS: and glycated haemoglobin concentration of 59 to 88 mmol/mol (7.5%-10.0%) were randomized (1:1) to preprandial subcutaneous injection of 10 μg exenatide (Byetta®) or placebo three times daily over 26 weeks as add-on treatment to existing insulin therapy. Reported markers of cardiovascular risk were secondary endpoints and were analyzed in a baseline-adjusted linear mixed model in the intention-to-treat population. The primary results of this study, the MAG1C (Meal-time Administration of exenatide for Glycaemic control in type 1 diabetes Cases) trial, were previously reported. RESULTS: Exenatide changed total fat mass by -2.6 kg (95% confidence interval [CI] -3.6; -1.6; P < 0.0001) and lean body mass by -1.1 kg (95% CI -1.9; -0.4; P = 0.01) compared with placebo, as assessed by dual-energy X-ray absorptiometry. Fat mass reductions were similar for central and peripheral fat mass. Exenatide did not change levels of interleukin-2 or -6; tumour necrosis factor-α; C-reactive protein; N-terminal prohormone of brain natriuretic peptide; or 8-oxo-7,8-dihydroguanosine (RNA oxidation marker) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (DNA oxidation marker). CONCLUSIONS: Exenatide added to insulin therapy in type 1 diabetes for 26 weeks resulted in body weight loss primarily from fat mass reduction, but had no effect on biomarkers of cardiovascular disease risk.
32
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Markers of Inflammation and Cardiovascular Disease
Thomas A. Pearson, George A. Mensah, R. Wayne Alexander et al. · Circulation · 2003 · 6.4K citations · Full text